ENSC

Ensysce Biosciences, Inc. Common Stock (ENSC) | Rumor.io

Ensysce Biosciences

ENSC

Attention (50-day avg)0%

Attention rank (50-day avg)#1,300

Bullish sentiment (50-day avg)61%

Price to earnings ratio0.02

Market capitalization7.8M

Earnings per share-2.56

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-10.2M

Social

What share of all stock conversation is about ENSC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% -0.01	0% 0

Sep 22

The company's management is questioned for a lack of data, with investors expressing distrust.
The dividend payout and potential short selling are discussed, with one user speculating about a short seller manipulating the price.
Some users believe the stock price is being artificially kept low by the company or a short seller, with one user speculating about a potential win for the stock.

Generated by AI

Sentiment

Of the messages about ENSC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	25%	27.27% +12.99	80.95% +10.73	78.47% -7.71
Bearish	75%	72.73% -12.99	19.05% -10.73	21.53% +7.71

Bullish· Aug 14

$ENSC has a fresh price target of $8.25, indicating a significant increase in value.
The company has seen a 60% earnings beat, with a $77 million acquisition, and is expected to release compliance news in the coming week.
The stock is expected to see a huge run, potentially a 500% month increase, and has a bullish setup if it closes above $0.40.

Bearish· Aug 14

The stock's price is being driven down by insiders liquidating their shares, which could lead to a structurally suppressed market.
The company's attempt to break through the $0.50 resistance level has failed, and the stock is now at risk of falling below $0.33.
Despite Zacks declaring the stock massively undervalued with a $8.25 price target, the current chart is "bizarre" and the stock's price is expected to continue falling.

Generated by AI

Topics

Of the messages about ENSC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	84.62%	39.53%
Technical Analysis	—	0%	11.54%	43.72%
Controversies	—	0%	3.85%	0.45%
Earnings	—	0%	0%	0.5%
Analysts	—	0%	0%	8.13%
Macro	—	0%	0%	7.67%

Analysts· Dec 9

Zacks Small-Cap Research issued a bullish report on Ensysce Biosciences, with a price target of $23.00.
Ensysce Biosciences shares have seen significant gains, with a 53% increase premarket, following the report.
The report's author, Brad Sorensen, is a Zacks analyst who has a track record of accurate predictions.

Announcements· Aug 6

Ensysce Biosciences, Inc. (ENSC) has completed the acquisition of Cy Biopharma and secured up to $77 million in private financing, including a $21.5 million initial private placement close and a potential follow-on tranche linked to a clinical milestone.
The acquisition adds Cy200, a neuroplastogenic therapy with FDA Orphan Drug Designation, to Ensysce's pipeline, and the company now operates with two clinical pillars: PF614-MPAR (opioid safety) and CY200.
The combined cash position is expected to fund CY200 through Phase 2 proof-of-concept data and into registrational development, and the announcement has eased concerns about near-term financing risk, with major healthcare-focused investors participating in the financing.

Technical Analysis· Aug 6

The technical analysis of Ensysce Biosciences, Inc. (ENSC) suggests a potential push back to $0.60 after a midday pullback, with a reclaim of $0.58 opening the door for a move back above $0.60.
Once ENSC definitively breaks and holds above $0.52, algorithmic targets sit at $0.58 and $0.63-$0.66, with a clear path toward the daily high of $0.98 if secondary momentum triggers.
A breakout above $1.00 could lead to a massive price increase, with a possible pattern resembling 4.96, 11.36, 28.04, depending on forced buying and the locked float.

Generated by AI

Community

Of the messages about ENSC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	78.26%	65.55%	44.05%
Newcomers	50%	21.74%	34.45%	55.95%

Regulars· Sep 10

Regulars are watching for a break above 50 cents, with potential resistance at higher levels.
Big money is likely to drive the price up as two main trials progress, with a goal of a 1000% payday.
The company is on track to meet the $1 requirement by February, but faces a risk of delisting if it fails to meet the equity requirement in its next report.

Newcomers· Aug 18

The newcomers are focused on the recent $77M acquisition and its impact on Ensysce Biosciences' cash reserves, which they believe makes dilution unnecessary and increases the company's value.
They are also discussing the director's purchase of $450,000 worth of shares at a 30% premium, which they see as a positive sign and a potential catalyst for the stock price to increase above $1.
The newcomers are analyzing the company's chart and technical indicators, such as the MACD oscillator and Bollinger Bands, and are optimistic about the stock's potential, with some even shorting the stock in anticipation of a price increase.

Generated by AI

SAN DIEGO, CA / ACCESS Newswire / September 14, 2026 / , Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced that Richard Langford, Chief Medical Officer of Cy Biopharma, has been selected to present in person at the U.

16d agoYahoo Finance

Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation

SAN DIEGO, CA / ACCESS Newswire / September 2, 2026 / , Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced its participation in the following upcoming investors conferences and industry events.

28d agoYahoo Finance

Ensysce completes enrollment in opioid overdose study

29d agoInvesting.com

Ensysce Biosciences Seeks Extended Nasdaq Compliance Grace Period

Detailed price information for Ensysce Biosciences Inc (ENSC-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about ENSC also mention

#	Name	Attention
1	Biofrontera Inc.BFRI	0%0
2	PTPI - Petros Pharmaceuticals, Inc.	——
3	iSpecimen Inc.ISPC	0%0
4	Society Pass IncorporatedSOPA	0%0
5	Longeveron Inc. Class A Common StockLGVN	0%0
6	Pasithea Therapeutics Corp.KTTA	0%0
7	Context Therapeutics Inc.CNTX	0%0
8	SGMA - SigmaTron International, Inc.	——
9	Immix Biopharma, Inc.IMMX	0.03%+0.03
10	Bluejay Diagnostics Inc.BJDX	0%0

Ensysce Biosciences, Inc. Common Stock

Healthcare
Biotechnology

Ensysce Biosciences, Inc. Common Stock represents ownership in Ensysce Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing prescription therapies for severe pain and central nervous system conditions. The company’s current work centers on proprietary drug-delivery and abuse-deterrence platforms, including Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR), which are designed to improve how certain medications are activated and to reduce the risks of misuse, abuse, and overdose. Its pipeline includes candidates for pain management, opioid protection, and attention deficit hyperactivity disorder, reflecting a focus on controlled pharmaceutical innovation rather than broad commercial medicines. Based in La Jolla, California, Ensysce Biosciences operates in the biotechnology and pharmaceuticals segment of the healthcare market, where it contributes to research-driven solutions aimed at safer treatment options for patients and clinicians.

Website

Location

7946 Ivanhoe Avenue

La Jolla, CA, 92037

United States

Social

What share of all stock conversation is about ENSC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% -0.01	0% 0

Sep 22

The company's management is questioned for a lack of data, with investors expressing distrust.
The dividend payout and potential short selling are discussed, with one user speculating about a short seller manipulating the price.
Some users believe the stock price is being artificially kept low by the company or a short seller, with one user speculating about a potential win for the stock.

Generated by AI

Sentiment

Of the messages about ENSC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	25%	27.27% +12.99	80.95% +10.73	78.47% -7.71
Bearish	75%	72.73% -12.99	19.05% -10.73	21.53% +7.71

Bullish· Aug 14

$ENSC has a fresh price target of $8.25, indicating a significant increase in value.
The company has seen a 60% earnings beat, with a $77 million acquisition, and is expected to release compliance news in the coming week.
The stock is expected to see a huge run, potentially a 500% month increase, and has a bullish setup if it closes above $0.40.

Bearish· Aug 14

The stock's price is being driven down by insiders liquidating their shares, which could lead to a structurally suppressed market.
The company's attempt to break through the $0.50 resistance level has failed, and the stock is now at risk of falling below $0.33.
Despite Zacks declaring the stock massively undervalued with a $8.25 price target, the current chart is "bizarre" and the stock's price is expected to continue falling.

Generated by AI

Topics

Of the messages about ENSC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	84.62%	39.53%
Technical Analysis	—	0%	11.54%	43.72%
Controversies	—	0%	3.85%	0.45%
Earnings	—	0%	0%	0.5%
Analysts	—	0%	0%	8.13%
Macro	—	0%	0%	7.67%

Analysts· Dec 9

Zacks Small-Cap Research issued a bullish report on Ensysce Biosciences, with a price target of $23.00.
Ensysce Biosciences shares have seen significant gains, with a 53% increase premarket, following the report.
The report's author, Brad Sorensen, is a Zacks analyst who has a track record of accurate predictions.

Announcements· Aug 6

Ensysce Biosciences, Inc. (ENSC) has completed the acquisition of Cy Biopharma and secured up to $77 million in private financing, including a $21.5 million initial private placement close and a potential follow-on tranche linked to a clinical milestone.
The acquisition adds Cy200, a neuroplastogenic therapy with FDA Orphan Drug Designation, to Ensysce's pipeline, and the company now operates with two clinical pillars: PF614-MPAR (opioid safety) and CY200.
The combined cash position is expected to fund CY200 through Phase 2 proof-of-concept data and into registrational development, and the announcement has eased concerns about near-term financing risk, with major healthcare-focused investors participating in the financing.

Technical Analysis· Aug 6

The technical analysis of Ensysce Biosciences, Inc. (ENSC) suggests a potential push back to $0.60 after a midday pullback, with a reclaim of $0.58 opening the door for a move back above $0.60.
Once ENSC definitively breaks and holds above $0.52, algorithmic targets sit at $0.58 and $0.63-$0.66, with a clear path toward the daily high of $0.98 if secondary momentum triggers.
A breakout above $1.00 could lead to a massive price increase, with a possible pattern resembling 4.96, 11.36, 28.04, depending on forced buying and the locked float.

Generated by AI

Community

Of the messages about ENSC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	78.26%	65.55%	44.05%
Newcomers	50%	21.74%	34.45%	55.95%

Regulars· Sep 10

Regulars are watching for a break above 50 cents, with potential resistance at higher levels.
Big money is likely to drive the price up as two main trials progress, with a goal of a 1000% payday.
The company is on track to meet the $1 requirement by February, but faces a risk of delisting if it fails to meet the equity requirement in its next report.

Newcomers· Aug 18

The newcomers are focused on the recent $77M acquisition and its impact on Ensysce Biosciences' cash reserves, which they believe makes dilution unnecessary and increases the company's value.
They are also discussing the director's purchase of $450,000 worth of shares at a 30% premium, which they see as a positive sign and a potential catalyst for the stock price to increase above $1.
The newcomers are analyzing the company's chart and technical indicators, such as the MACD oscillator and Bollinger Bands, and are optimistic about the stock's potential, with some even shorting the stock in anticipation of a price increase.

Generated by AI

Ensysce Biosciences

Social

Sep 22

Bullish· Aug 14

Bearish· Aug 14

Analysts· Dec 9

Announcements· Aug 6

Technical Analysis· Aug 6

Regulars· Sep 10

Newcomers· Aug 18

Ensysce submits Phase 2a protocol for CRPS treatment CY200

Ensysce hosts symposium at PainWeek, attends FDA hearing

Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs

Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation

Ensysce completes enrollment in opioid overdose study

Ensysce Biosciences Seeks Extended Nasdaq Compliance Grace Period

Also Discussed

Ensysce Biosciences, Inc. Common Stock

Company Information

Location

Ensysce submits Phase 2a protocol for CRPS treatment CY200

Ensysce hosts symposium at PainWeek, attends FDA hearing

Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs

Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation

Ensysce completes enrollment in opioid overdose study

Ensysce Biosciences Seeks Extended Nasdaq Compliance Grace Period

Also Discussed

Social

Sep 22

Bullish· Aug 14

Bearish· Aug 14

Analysts· Dec 9

Announcements· Aug 6

Technical Analysis· Aug 6

Regulars· Sep 10

Newcomers· Aug 18